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| INTRODUC TI ON
Liver cancer is the second most common cause of death from cancer and over 90% of cases are hepatocellular carcinoma (HCC). The diagnosis of HCC at an early stage is very important to improve disease prognosis. [1] [2] [3] Unfortunately, only about 30% of HCC in developed countries are diagnosed at an early stage and the figure is lower in developing countries. 4 At present, the diagnosis of HCC mainly depends on imaging techniques and serum biomarkers.
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The sensitivities of imaging techniques, including ultrasonography, computed tomography and magnetic resonance imaging, vary greatly depending on the lesion size and operator experience. For histologically well-differentiated tumours with diameter smaller than 2 cm, usually referring to as early HCC, their sensitivities are all below 50% even for experienced pathologists. 5, 6 The diagnostic sensitivity of serum markers, α-foetoprotein, is around 60% for early HCC patients. 7 Thus, tissue biopsy becomes a necessary method for the early diagnosis of HCC. However, because the biopsy location may be inaccurate, 8 the false-negative rate of diagnosis based on biopsy specimens, with inaccurately sampled adjacent non-tumour tissues (cirrhosis or normal) of HCC, is about 30% and it increases to 50% in small biopsy specimens. 9, 10 Therefore, it is necessary to develop signatures to distinguish HCC from tissues of cirrhosis patients based on a minimum biopsy specimen even when the biopsy location is inaccurate, which would be possible because the adjacent nontumour liver tissues of HCC patients might have some molecular characteristics of HCC. [11] [12] [13] However, previously reported diagnos- 
| MATERIAL S AND ME THODS

| Data sources and data preprocessing
Multiple gene expression profiles were collected from Gene Expression
Omnibus repository (GEO), as described in Table 1 . Especially, 81 HCC patients even using inaccurately sampled biopsy specimens, which can aid early diagnosis of hepatocellular carcinoma.
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Key points
• This study used the within-sample relative expression orderings (REOs) to develop a signature to aid early HCC diagnosis using biopsy specimens.
• The signature consisting of 19 gene pairs can distinguish both HCC tissues and tumour-adjacent tissues from cirrhosis tissues of non-HCC patients even using inaccurately sampled biopsy specimens.
• For biopsy specimens, 95.7% of 141 HCC tissues and all of 108 cirrhosis tissues of non-HCC patients were correctly classified.
• For surgical resection specimens, 99.7% of 733 HCC specimens were correctly classified, while 17.0% of 47 cirrhosis from non-HCC patients waiting for liver transplantation were classified to HCC.
samples in the data set GSE54236 were collected from biopsy specimens with 500 ng total RNA for each sample measured by the Agilent platform, and 60 HCC samples in the data set GSE64041 were also collected from biopsy specimens with 250 ng total RNA for each sample measured by the Affymetrix platform. The 216 cirrhosis samples of non-HCC patients in the data set GSE15654 were obtained from small biopsies followed by formalin fixation (typically 10 × 1 mm pieces of tissue). 
Then, the Ensembl gene IDs corresponding to the unique Entrez gene
IDs of protein coding genes were used for further analysis. CoHCC and CHCC denote cirrhosis tissues of non-HCC patients and adjacent cirrhosis tissues of HCC patients respectively. a Samples collected by biopsy.
| Identification of the qualitative REO-based diagnostic signature
the reversal degree of the gene pair between HCC and cirrhosis of non-HCC:
The larger this geometric mean, the larger the reversal degree of the REO of the gene pair is between the 2 types of samples. All reversal gene pairs were sorted in a descending order according to their reversal degrees. The gene pair with the largest reversal degree was selected as the seed, and then a forward selection procedure was used to search an odd number of optimal subset of the reversal gene pairs to achieve the highest classification accuracy based on the majority voting rule. For a given sample, when more than a half gene pairs in the signature show the REOs for HCC, the sample is classified to HCC; otherwise, it is classified to cirrhosis of non-HCC.
| Performance evaluation
Hepatocellular carcinoma samples and cirrhosis samples of non-HCC from different data sets were directly pooled together. The sensitivity, specificity and accuracy were used to evaluate the performance of the signature. Here, the sensitivity was defined as the proportion of correctly identified HCC samples in all HCC samples and the specificity was (iv) The area under curve (AUC) was calculated with the nonparametric Hanley-McNeil algorithm 43 and 95% confidence intervals for AUC was determined using an approximate normal distribution.
| Statistical analysis
All statistical analyses were performed using the R 3.1.1 language (http://www.r-project.org/).
| RE SULTS
| Identification of the qualitative diagnostic signature
The flow chart of this study is described in Figure 1 . Firstly, we identified a total of 35,987,367 gene pairs with the same REOs in more than 85% of the 491 HCC samples collected from 3 data sets of GSE14323, GSE14520 and GSE63898. Similarly, we identi- Figure 2 and Table 2 ). With this signature, based on the majority voting rule, 99.8% HCC samples and 99.3% cirrhosis samples of non-HCC patients in the training data sets were correctly classified. The detailed classification performance of the signature in each of the training data set was shown in Table S1 .
| Validation of the diagnostic signature in independent data sets
Then the 19-gene-pair was validated in multiple data sets of biopsy and surgical resection samples respectively.
For biopsy samples in the data set GSE64041 with 250 ng RNA for each sample, 100.0% of the 60 HCC samples were correctly classified to HCC by the 19-gene-pair. In the data set GSE54236 with 500 ng RNA for each sample, 92.6% of the 81 HCC samples were classified to HCC. In other word, 95.7% of 141 HCC tissues were correctly classified. The accuracy was 97.6% and the AUC was 0.9999 (95% CI = 0.9705-1; shown in Figure 3A) . Meanwhile, 100.0% of the 108 cirrhosis biopsy samples of non-HCC patients in the GSE15654-V subset were correctly classified. These results validated that the signature could discriminate HCC from cirrhosis samples of non-HCC.
Moreover, 100.0% of the 60 HCC adjacent normal biopsy tissues in the data set GSE64041 and 77.5% of the 80 HCC adjacent cirrhosis biopsy tissues in the data set GSE54236 were classified to HCC.
The results validated that, even using the inaccurately sampled biopsy specimens, the 19-gene-pair could classify most of tumour-adjacent tissues of HCC patients to HCC. For surgical resection samples, as shown in Table 3 , 99.7% of the 733 HCC samples integrated from 7 data sets were correctly classified. Moreover, 96.1% of the 254 HCC adjacent cirrhosis samples and 95.9% of the 538 HCC adjacent normal samples were classified to HCC (Table S2 ). The accuracy was 98.8%
and the AUC was 0.9452 (95% CI = 0.8803-1; shown in Figure 3B ).
The results suggested that the 19-gene-pair could identify most of adjacent non-tumour liver tissues from HCC patients to HCC. On the contrary, 83.0% of the 47 patients with advanced cirrhosis of the liver terminal waiting for liver transplantation 17 from the data set
GSE17967 were classified to non-HCC, whereas 17.0% of these samples were classified as HCC. The result indicated that the signature might be able to identify cirrhosis patients at high risk of HCC because it is very possible that a certain percentage of the patients with long-lasting cirrhosis could have already gained some characteristics of HCC.
Notably, the 19 gene-pair signature could also be validated using the RNA-Seq data set of HCC from TCGA: all the 355 HCC samples and 42 HCC adjacent non-tumour tissues were correctly classified to HCC. However, because we could find RNA-Seq data of cirrhosis tissue samples from non-HCC patients in neither TCGA nor GEO,
we were unable to test the signature on cirrhosis samples. Notably, and these functions need to be further studied in the further work.
| D ISCUSS I ON
Notably, the biopsy samples analysed in this study had relatively large amount of tissues to yield about 250-500 ng total RNA. 31, 32 However, under many practical situations with a needle for biopsy, it is difficult to obtain biopsy specimens to yield sufficient quantity of RNA molecules for gene expression profiling or other molecular measurements. Gene A has a higher expression level than Gene B in HCC patients compared with cirrhosis tissues of non-HCC patients.
The clinical value of the 19-gene-pair for early diagnosis of HCC is worthy to be further verified.
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